1. Pink Sheet
  2. >>Legislation

‘Wildcard’ Patents: Why A REVAMP-ed Proposal Might Work In 2017

 
• By Michael McCaughan and Laura Helbling

Before election day, the idea of a new transferrable exclusivity incentive seemed like an extreme long shot for enactment. But now advocates think it has a real chance – and a strategy to redraft the idea to answer Democratic critics and avoid a high CBO score.

Red and blue arrow elevators with businessmen going up and down.

It didn’t take long for an audience of public health professionals focused on antibiotic resistance to find a silver lining in the Nov. 8 election results: the GOP victories mean that there is a very real chance for enactment of a “wildcard” patent extension to support development of drugs for emerging infections.

The organizers of a Nov. 9 Duke Margolis Center workshop on incentives for antibiotic development probably expected a very different climate for their post-Election discussion. They had prepared to discuss...

More from Legislation

EMA: ‘Sad To See’ Member States Against Patient Engagement Under EU Pharma Reform

 
• By Eliza Slawther

The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.

BIOSECURE Act Returning, Privacy, Gain-of-Function Bills Coming, Senate Sponsor Says

 
• By Laura Helbling

Legislation prohibiting work with certain Chinese biopharma firms will be reintroduced soon, Democratic Sen. Gary Peters said. And it will not be the only bill tied to international biotech competition and security concerns that will be considered.

Pharma DTC Ad Tax Break Targeted By US HHS, Congress

 
• By Derrick Gingery

Health and Human Services Secretary Robert F. Kennedy Jr. said a policy that would remove the tax write-off for pharma advertising expenses would be coming in a few weeks.

Korean Pharma Industry Proposes Policies As Election Nears

 
• By Jung Won Shin

As South Korea gears up for a snap presidential election, its biopharma industry proposes key desired policies to candidates, most of whom have not laid out detailed plans of their own for the sector.

More from Pink Sheet